# Hospital Universitario 12 de Octubre

Source: https://onco.cc/institutions/12-de-octubre/  
OnCo record `12-de-octubre` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

One of Madrid's largest hospitals, a leading site for lung cancer and myeloma trials and for academic CAR-T development.

## Summary

The Hospital Universitario 12 de Octubre and its research institute i+12 host the H12O-CNIO Lung Cancer Clinical Research Unit led by Luis Paz-Ares, one of the most active investigators in small-cell and non-small-cell lung cancer trials including the tarlatamab programme, and a haematology department under Joaquín Martínez-López that pioneered next-generation sequencing for minimal residual disease in myeloma and co-developed the academic BCMA CAR-T ARI-0002h with Hospital Clínic. The hospital is a major transplant centre, runs paediatric oncology and neuro-oncology services and a phase 1 unit. Its proximity to the CNIO underpins joint translational programmes.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: H12O; i+12 Research Institute
- City: Madrid, ES
- Type: hospital
- Website: https://www.comunidad.madrid/hospital/12octubre/

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hospital_Universitario_12_de_Octubre
- Homepage: https://www.comunidad.madrid/hospital/12octubre/
- i+12: https://imas12.es

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [DLL3](https://onco.cc/targets/dll3/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- institutions: [Centro Nacional de Investigaciones Oncológicas (CNIO)](https://onco.cc/institutions/cnio/), [Hospital Clínic de Barcelona / IDIBAPS](https://onco.cc/institutions/hospital-clinic-barcelona/), [Hospital Clínico San Carlos](https://onco.cc/institutions/clinico-san-carlos/), [Hospital Universitario de La Princesa](https://onco.cc/institutions/la-princesa/), [Hospital Universitario Puerta de Hierro Majadahonda](https://onco.cc/institutions/puerta-de-hierro/), [Hospital Universitario Ramón y Cajal](https://onco.cc/institutions/ramon-y-cajal/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- people: [Carmen Martínez de Pancorbo González](https://onco.cc/people/carmen-martinez-de-pancorbo-gonzalez/), [Joaquín Martínez-López](https://onco.cc/people/joaquin-martinez-lopez/), [Luis Paz-Ares](https://onco.cc/people/luis-paz-ares/)

---
JSON: https://onco.cc/api/v1/entities/12-de-octubre.json